CollPlant Biotechnologies
CLGN
17 hedge funds and large institutions have $9.14M invested in CollPlant Biotechnologies in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 3 closing their positions.
7% more capital invested
Capital invested by funds: $8.55M → $9.14M (+$592K)
9% more call options, than puts
Call options by funds: $12K | Put options by funds: $11K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.16% less ownership
Funds ownership: 13.66% → 12.5% (-1.2%)
6% less funds holding
Funds holding: 18 → 17 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SDJVC
St. Denis J. Villere & Co
New Orleans,
Louisiana
|
+$334K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$36.8K |
| 3 |
BFEC
Benjamin F. Edwards & Company
St. Louis,
Missouri
|
+$27.9K |
| 4 |
JP Morgan Chase
New York
|
+$2.03K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
-$795K |
| 2 |
PA
Pinnacle Associates
New York
|
-$55.8K |
| 3 |
PA
Parallel Advisors
San Francisco,
California
|
-$46.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$31.7K |
| 5 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$4.22K |
CLGN Hedge Fund Activity: Q4 2023 in Review
17 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in CollPlant Biotechnologies (CLGN) for Q4 2023, worth a combined $9.14M — up 6.9% from $8.55M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CLGN and 2 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 2 added.
The largest buyer was St. Denis J. Villere & Co, adding an estimated $334K. The largest seller was Roumell Asset Management, cutting an estimated $795K.
- 17 institutional investors held CollPlant Biotechnologies (CLGN) as of Q4 2023, down from 18 in Q3 2023.
- Funds reported $9.14M of CollPlant Biotechnologies stock for Q4 2023, up 6.9% quarter-over-quarter.
- 2 funds opened new CollPlant Biotechnologies positions in Q4 2023 and 3 closed out, a net change of -1 holder.
- The largest CollPlant Biotechnologies buyer in Q4 2023 was St. Denis J. Villere & Co, an estimated $334K added.
- The largest CollPlant Biotechnologies seller in Q4 2023 was Roumell Asset Management, an estimated $795K sold.
Based on aggregated 13F filings for Q4 2023.